Nventa granted European patents for HPV vaccine

By Lisa Kerner

Charlotte, N.C., June 20 - The European Patent Office has granted two patents to Nventa Biopharmaceuticals Corp. related to HspE7, its investigational therapeutic vaccine for the treatment of human papillomavirus (HPV)-related diseases.

The first patent covers the use of Nventa's HPV-16 based CoVal fusion protein HspE7 for the treatment of HPV-related diseases not caused by HPV-16.

Nventa is also provided protection around observations made from earlier studies that show clinically relevant responses in diseases such as genital warts, according to a company news release.

The second patent covers HspE7 with specific claims for the composition and use of Hsp-HPV E7 fusion proteins.

One of the most common sexually transmitted diseases, HPV infects an estimated 80% of sexually active men and women. HPV infection can result in internal and external genital warts and precancerous conditions, such as cervical and anal dysplasia that can progress to cervical, anal and head and neck cancers.

San Diego-based Nventa develops therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by HPV.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.